Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

EGFR and some of the cognate ligands extensively traffic in extracellular vesicles (EVs) from different biogenesis pathways. EGFR belongs to a family of four homologous tyrosine kinase receptors (TKRs). This family are one of the major drivers of cancer and is involved in several of the most frequen...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Zanetti-Domingues, LC, Martin-Fernandez, ML, Huber, V
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	MDPI 2020

Ижил төстэй зүйлс

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
-н: Laura C. Zanetti-Domingues, зэрэг
Хэвлэсэн: (2020-11-01)

Cooperation and interplay between EGFR signalling and extracellular vesicle biogenesis in cancer
-н: Zanetti-Domingues, LC, зэрэг
Хэвлэсэн: (2020)

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer
-н: Laura C. Zanetti-Domingues, зэрэг
Хэвлэсэн: (2020-12-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
-н: Xu H, зэрэг
Хэвлэсэн: (2019-07-01)

Extracellular Vesicles As Mediators of Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Preclinical Models
-н: M. Pérez-Capó, зэрэг
Хэвлэсэн: (2023-11-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
-н: Lihua Huang, зэрэг
Хэвлэсэн: (2015-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
-н: Lu Yang, зэрэг
Хэвлэсэн: (2022-06-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
-н: Yao Li, зэрэг
Хэвлэсэн: (2024-12-01)

HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles
-н: J.-H. Lee, зэрэг
Хэвлэсэн: (2018-02-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
-н: Cornelius Hempel, зэрэг
Хэвлэсэн: (2017-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
-н: Igor Makhlin, зэрэг
Хэвлэсэн: (2019-11-01)

An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
-н: Katri Vaparanta, зэрэг
Хэвлэсэн: (2022-11-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
-н: Tasia Amelia, зэрэг
Хэвлэсэн: (2022-01-01)

Extracellular vesicle-associated tyrosine kinase-like orphan receptors ROR1 and ROR2 promote breast cancer progression
-н: Barnabas Irmer, зэрэг
Хэвлэсэн: (2023-07-01)

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
-н: Aude I. Ségaliny, зэрэг
Хэвлэсэн: (2015-03-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
-н: Panupong Mahalapbutr, зэрэг
Хэвлэсэн: (2024-02-01)

Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer
-н: Ramya Lakshmi Rajendran, зэрэг
Хэвлэсэн: (2021-02-01)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
-н: Shannon S. Zhang, MD, зэрэг
Хэвлэсэн: (2022-08-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
-н: Kenichi Suda, зэрэг
Хэвлэсэн: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
-н: Xingyuan Li, зэрэг
Хэвлэсэн: (2023-10-01)

Mechanisms of receptor tyrosine kinase activation in cancer
-н: Zhenfang Du, зэрэг
Хэвлэсэн: (2018-02-01)

Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
-н: Kinlin L Chao, зэрэг
Хэвлэсэн: (2012-01-01)

Action Mechanisms of Small Extracellular Vesicles in Inflammaging
-н: Rocío Mato-Basalo, зэрэг
Хэвлэсэн: (2022-04-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
-н: Marcin Skrzypski, зэрэг
Хэвлэсэн: (2017-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
-н: Keigo Kobayashi
Хэвлэсэн: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
-н: Daniel B Costa, зэрэг
Хэвлэсэн: (2007-10-01)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
-н: Xuedi Zhang, зэрэг
Хэвлэсэн: (2022-11-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
-н: Zhe Zhang, зэрэг
Хэвлэсэн: (2019-11-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
-н: Tim Fischer, зэрэг
Хэвлэсэн: (2018-01-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
-н: K. K. Laktionov, зэрэг
Хэвлэсэн: (2019-06-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
-н: Tatsuki Shibuta, зэрэг
Хэвлэсэн: (2022-06-01)

Proteolytic Cleavage of Receptor Tyrosine Kinases
-н: Hao Huang
Хэвлэсэн: (2021-04-01)

Receptor Tyrosine Kinases — Expanding Horizons
-н: Sassan Hafizi
Хэвлэсэн: (2014-06-01)

Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain.
-н: Kenji Hanamura, зэрэг
Хэвлэсэн: (2017-07-01)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
-н: Ichiro N. Maruyama
Хэвлэсэн: (2014-04-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
-н: Jihene Elloumi-Mseddi, зэрэг
Хэвлэсэн: (2013-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
-н: Nathaniel J. Myall, MD, зэрэг
Хэвлэсэн: (2025-02-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
-н: D. D. SAKAEVA
Хэвлэсэн: (2017-06-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
-н: Soomin Kim, зэрэг
Хэвлэсэн: (2025-02-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
-н: Wu Z, зэрэг
Хэвлэсэн: (2019-10-01)